NCT01836458View on ClinicalTrials.gov

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Malaria
Interventions
DRUG

KAE609

Patients will receive KAE609 single dose at a different dose level in each cohort.

Trial Locations (1)

Unknown

Novartis Investigative Site, Ho Chi Minh City

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY